June 29, 2022
Recent prospective studies suggest that more than half of patients with Type 2 diabetes have concomitant NAFLD and more than one in three have NASH.
Other recent research tells us that patients with both diseases are at significantly increased risk of heart disease and cancer and are likely to have lower quality-of-life scores when compared to patients with T2D alone.
Join endocrinologist Kenneth Cusi, MD, forecaster/podcaster Roger Green, and their renowned guests to focus on the scale of the problem (HINT: large and scary!) and practical things you can do today to diagnose and treat these patients more effectively.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
Michelle Long and Mazen Noureddin join the Surfers (including Stephen Harrison) for a wrap-up of the major stories of #ILC2022. Much of the episode focuses on NASH Drug Development, with side conversations about the value and challenges of relying on FIB-4 or, even worse, ALT in patient screening and diagnosis.
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among Type 2 Diabetes Mellitus patients
Mazen Noureddin and Ian Rowe join Louise Campbell and Jörn Schattenberg to discuss an important discussion about the roles different NITs will play in the future of NASH diagnosis, treatment and monitoring. Then Louise talks with PBC Foundation CEO Robert Mitchell-Thain about
Michelle Long and Zobair Younossi join the Surfers to discuss the first three days of #ILC2022.
Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that reported, in a prospective random sample of 835 people with a median age of 55, NAFLD prevalence as being 37%, NASH as being 14% and advanced fibrosis as being 6% in a random asymptomatic patients. Among patient with Type 2 Diabetes, NAFLD prevalence was 70% and NASH was 35%.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at #ILC2022. This conversation focuses largely on OS025 Non-invasive fibrosis scores as prognostic biomarkers of liver events, cardiovascular events and all-cause mortality in people with obesity and/or type 2 diabetes in the UK: a longitudinal cohort study.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on the impact of NAFLD on quality of life.
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among
Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that
In this Premier episode of The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide, key opinion leaders Doctors
